top of page

Company agrees to $35-million settlement over kidney transplant – 21 News Now, More Local News

Company agrees to $35-million settlement over kidney transplant drug

Posted: Aug 06, 2014 9:34 AM

Updated: Aug 06, 2014 9:42 AM


Ohio Attorney General Mike DeWine has announced that Ohio and 41 other attorneys general have reached a $35 million settlement to resolve allegations that Wyeth Pharmaceuticals Inc. unlawfully promoted Rapamune, a drug approved for use by kidney transplant patients. Pfizer Inc., the parent company of Wyeth, agrees to be bound by the settlement.

Ohio will receive $984,812 as part of the settlement.

Rapamune is currently approved by the U.S. Food and Drug Administration (FDA) to prevent the body from rejecting an organ after kidney transplant surgery.

The attorneys general allege that Wyeth violated state consumer protection laws by misrepresenting the uses and benefits of Rapamune, relating to: (1) unapproved use following an organ transplant other than a kidney transplant; (2) unapproved protocol of converting patients to Rapamune after they first received a different immunosuppressive drug; and (3) use in unapproved drug combinations.

Today’s proposed settlement, which must be approved by the court, requires Pfizer to ensure that its marketing and promotional practices do not unlawfully promote Rapamune or any Pfizer product.

Specifically, Pfizer shall not:

Make, or cause to be made, any written or oral claim that is false, misleading, or deceptive regarding any Pfizer product;

Make any claim comparing the safety or effectiveness of a Pfizer product to another product when that claim is not supported by substantial evidence as defined by federal law and regulations;

Promote any Pfizer product for off-label uses;

Include mechanisms in its financial incentives to provide incentive compensation for sales that may be attributable to the off-label uses of any Pfizer product;

Affirmatively seek the inclusion of Rapamune in hospital protocols or standing orders unless Rapamune has been approved by the FDA for the indication for which it is to be included in the protocol or standing order;

Disseminate information describing any off-label or unapproved use of Rapamune unless such information and materials comply with applicable FDA regulations and the recommended actions in FDA Guidances for Industry; or

Seek to influence the prescribing of Rapamune in hospitals or transplant centers in any manner (including through funding clinical trials) that does not comply with the federal anti-kickback statute.

In Ohio, a complaint was filed and a proposed judgment order was submitted today to the Franklin County Common Pleas Court..

1 view0 comments
bottom of page